Menu Search
Equities

Marinomed Biotech AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
93Z:FRA

Marinomed Biotech AG

Actions
  • Price (EUR)16.75
  • Today's Change0.10 / 0.60%
  • Shares traded100.00
  • 1 Year change+27.86%
  • Beta0.1683
Data delayed at least 15 minutes, as of Feb 11 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH, is an Austria-based biopharmaceutical company. The Company operates in two segments such as Virology and Immunology. It develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose, platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients, this technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases.

  • Revenue in EUR (TTM)9.46m
  • Net income in EUR16.14m
  • Incorporated2006
  • Employees42.00
  • Location
    Marinomed Biotech AGHovengasse 25KORNEUBURG 2100AustriaAUT
  • Phone+43 226290300
  • Fax+43 226 290300500
  • Websitehttps://www.marinomed.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.